Progranulin is a secreted growth factor associated with multiple physiological functions in ischemic pathophysiology. However, it is still not fully understood how progranulin is involved in ischemic lesion and cardiac remodeling after myocardial infarction (MI). In this study, we investigated the effects of progranulin on myocardial ischemia and reperfusion injury. We investigated progranulin expression using Western blotting and immunostaining after permanent left coronary artery (LCA) occlusion in mice. Infarct size and the number of infiltrating neutrophils were measured 24 h after permanent LCA occlusion. Recombinant mouse progranulin was administered before LCA occlusion. In addition, we evaluated cardiac function using cardiac catheterization and echocardiography, and fibrosis size by Masson's trichrome staining after myocardial ischemia/reperfusion in rabbits. Recombinant human progranulin was administered immediately after induction of reperfusion. Progranulin expression increased in the myocardial ischemic area 1, 3, and 5 days after permanent LCA occlusion in mice. The administration of recombinant mouse progranulin significantly attenuated infarct size and infiltrating neutrophils 24 h after permanent LCA occlusion in mice. We also found that administration of recombinant human progranulin ameliorated the deterioration of cardiac dysfunction and fibrosis after myocardial ischemia/reperfusion in rabbits. These findings suggest that progranulin may protect myocardial ischemia/reperfusion injury. Cardiovascular diseases (CVD) are disorders of the heart and blood vessels, and a leading cause of death worldwide despite therapeutic intervention 1. The worldwide prevalence of CVD is approximately 17.7 million people every year, and CVD accounts for 30% of global mortality 2. Acute myocardial infarction (AMI) in CVD leads to the sudden cardiac death and heart failure, which is a devastating complication 3. AMI is an event of myocardial necrosis by acute thrombotic obstructions of blood flow in coronary arteries. Rapid reperfusion of coronary arteries achieved by percutaneous coronary intervention (PCI) and thrombolysis benefits patients with AMI 4,5. However, there are several problems with current therapy. Myocardial ischemia/reperfusion (I/R) injury increases myocardial infarct size and decreases blood flow associated with microcirculatory disturbances 6-8. Enlargement of I/R injury from delayed reperfusion therapy increases the risk of subsequent developments of cardiac rupture and heart failure, in patients with AMI 7. In addition, these therapies and subsequent therapeutic interventions increase the mental and economic burden on patients 9,10. Therefore, it is important to elucidate the pathogenesis of myocardial I/R injury and explore novel therapeutic targets for AMI. Progranulin is a secreted growth factor associated with embryonic development 11 , wound healing 12 , and inflammation 13,14. Progranulin expression is observed in macrophages, neutrophils and skeletal myocytes 15,16 .